Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Disease Solution Services generated ¥244.078 million, up 81.2% year on year, due to the recognition of revenue from a new PHR service commissioned by a pharmaceutical company. Welby Mykarte Services generated ¥132.089 million, down 13.7% year on year, mainly due to timing differences affecting certain projects. Selling, general and administrative expenses increased 13.9% year on year due to recruitment and development investments, among other factors.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥376 million (YoY +30.7%) |
| Operating profit | ¥-256 million |
| Ordinary income | ¥-257 million |
| Profit attributable to owners of the parent | ¥-223 million |
| Net income per share | △¥26.70 |
| Equity ratio | End of the current fiscal period 6.7 / End of previous period 20.9 |
| Total assets | ¥844 million |
| Net assets | ¥108 million |
| Full-year earnings forecast | Net Sales ¥1,466 million (YoY +130.5%) / Operating profit ¥-30 million / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥18,947 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 8,435,582 |
| Treasury Shares at Period-End | 30 |
| Factors Behind Changes in Business Performance | Disease Solution Services generated ¥244.078 million, up 81.2% year on year, due to the recognition of revenue from a new PHR service commissioned by a pharmaceutical company. Welby Mykarte Services generated ¥132.089 million, down 13.7% year on year, mainly due to timing differences affecting certain projects. Selling, general and administrative expenses increased 13.9% year on year due to recruitment and development investments, among other factors. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Disease Solution Services posted higher revenue due to the recognition of revenue from a new PHR service commissioned by a pharmaceutical company, while Welby Mykarte Services posted lower revenue due to timing differences affecting certain projects. Selling, general and administrative expenses also increased due to recruitment and development investments aimed at expanding the business.